E-Mail CLEVELAND--Researchers at Case Western Reserve University, using artificial intelligence (AI) to analyze simple tissue scans, say they have discovered biomarkers that could tell doctors which lung cancer patients might actually get worse from immunotherapy. Until recently, researchers and oncologists had placed these lung cancer patients into two broad categories: those who would benefit from immunotherapy, and those who likely would not. But a third category--patients called hyper-progressors who would actually be harmed by immunotherapy, including a shortened lifespan after treatment--has begun to emerge, said Pranjal Vaidya, a PhD student in biomedical engineering and researcher at the university's Center for Computational Imaging and Personalized Diagnostics (CCIPD).